{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Carcinomas&page=9",
    "query": {
      "condition": "Neuroendocrine Carcinomas",
      "page": 9
    },
    "page_size": 10
  },
  "pagination": {
    "page": 9,
    "page_size": 10,
    "total_count": 952,
    "total_pages": 96,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Carcinomas&page=10&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Carcinomas&page=8&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-18T20:13:16.792Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03420963",
      "title": "Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Cutaneous Melanoma",
        "Recurrent Lip and Oral Cavity Carcinoma",
        "Recurrent Malignant Endocrine Neoplasm",
        "Recurrent Malignant Female Reproductive System Neoplasm",
        "Recurrent Malignant Male Reproductive System Neoplasm",
        "Recurrent Malignant Mesothelioma",
        "Recurrent Malignant Neoplasm of Multiple Primary Sites",
        "Recurrent Malignant Oral Neoplasm",
        "Recurrent Malignant Pharyngeal Neoplasm",
        "Recurrent Malignant Skin Neoplasm",
        "Recurrent Malignant Soft Tissue Neoplasm",
        "Recurrent Malignant Solid Neoplasm",
        "Recurrent Malignant Thyroid Gland Neoplasm",
        "Recurrent Malignant Urinary System Neoplasm",
        "Refractory Cutaneous Melanoma",
        "Refractory Malignant Bone Neoplasm",
        "Refractory Malignant Endocrine Neoplasm",
        "Refractory Malignant Female Reproductive System Neoplasm",
        "Refractory Malignant Male Reproductive System Neoplasm",
        "Refractory Malignant Mesothelioma",
        "Refractory Malignant Neoplasm of Multiple Primary Sites",
        "Refractory Malignant Oral Neoplasm",
        "Refractory Malignant Pharyngeal Neoplasm",
        "Refractory Malignant Skin Neoplasm",
        "Refractory Malignant Soft Tissue Neoplasm",
        "Refractory Malignant Solid Neoplasm",
        "Refractory Malignant Thyroid Gland Neoplasm",
        "Refractory Malignant Urinary System Neoplasm"
      ],
      "interventions": [
        {
          "name": "Cord Blood-derived Expanded Allogeneic Natural Killer Cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "12 Months to 40 Years"
      },
      "enrollment_count": 12,
      "start_date": "2018-08-31",
      "completion_date": "2026-02-26",
      "has_results": false,
      "last_update_posted_date": "2026-03-20",
      "last_synced_at": "2026-11-18T20:13:16.792Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03420963"
    },
    {
      "nct_id": "NCT07285044",
      "title": "The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Amyloidosis",
        "Basal Cell Carcinoma",
        "Biliary Tract Carcinoma",
        "Bladder Carcinoma",
        "Breast Carcinoma",
        "Cervical Carcinoma",
        "Colorectal Carcinoma",
        "Endometrial Carcinoma",
        "Fallopian Tube Carcinoma",
        "Gastroesophageal Junction Carcinoma",
        "Glioblastoma",
        "Head and Neck Carcinoma",
        "Hematopoietic and Lymphatic System Neoplasm",
        "Hepatocellular Carcinoma",
        "Hodgkin Lymphoma",
        "Lung Carcinoma",
        "Malignant Solid Neoplasm",
        "Mantle Cell Lymphoma",
        "Melanoma",
        "Merkel Cell Carcinoma",
        "Multiple Myeloma",
        "Myelodysplastic Syndrome",
        "Ovarian Carcinoma",
        "Pancreatic Carcinoma",
        "Primary Peritoneal Carcinoma",
        "Prostate Carcinoma",
        "Renal Cell Carcinoma",
        "Squamous Cell Carcinoma",
        "Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Cancer Therapeutic Procedure",
          "type": "DRUG"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2025-12-18",
      "completion_date": "2027-05-15",
      "has_results": false,
      "last_update_posted_date": "2026-09-30",
      "last_synced_at": "2026-11-18T20:13:16.792Z",
      "location_count": 1,
      "location_summary": "Jacksonville, Florida",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07285044"
    },
    {
      "nct_id": "NCT00304460",
      "title": "Mechanism of Action of High-Dose IL-2 (Aldesleukin) in Metastatic Melanoma and Kidney Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Melanoma",
        "Renal Cell Cancer"
      ],
      "interventions": [
        {
          "name": "aldesleukin",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 138,
      "start_date": "2006-03-13",
      "completion_date": "2014-02-27",
      "has_results": false,
      "last_update_posted_date": "2019-12-12",
      "last_synced_at": "2026-11-18T20:13:16.792Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00304460"
    },
    {
      "nct_id": "NCT05577182",
      "title": "Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Malignancies"
      ],
      "interventions": [
        {
          "name": "INCA32459-101",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2023-01-05",
      "completion_date": "2025-10-13",
      "has_results": false,
      "last_update_posted_date": "2025-11-03",
      "last_synced_at": "2026-11-18T20:13:16.792Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • Houston, Texas",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05577182"
    },
    {
      "nct_id": "NCT01496313",
      "title": "To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Thyroid Cancer"
      ],
      "interventions": [
        {
          "name": "300mg vandetanib",
          "type": "DRUG"
        },
        {
          "name": "150mg vandetanib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 81,
      "start_date": "2012-06-08",
      "completion_date": "2024-07-11",
      "has_results": true,
      "last_update_posted_date": "2025-10-03",
      "last_synced_at": "2026-11-18T20:13:16.792Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01496313"
    },
    {
      "nct_id": "NCT02452424",
      "title": "A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Melanoma",
        "Non-small Cell Lung Cancer",
        "Squamous Cell Carcinoma of the Head and Neck",
        "Gastrointestinal Stromal Tumor (GIST)",
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "PLX3397",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Daiichi Sankyo",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 78,
      "start_date": "2015-07-02",
      "completion_date": "2018-10-12",
      "has_results": true,
      "last_update_posted_date": "2020-03-05",
      "last_synced_at": "2026-11-18T20:13:16.792Z",
      "location_count": 12,
      "location_summary": "Scottsdale, Arizona • Greenbrae, California • Los Angeles, California + 7 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02452424"
    },
    {
      "nct_id": "NCT00113360",
      "title": "RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neuroendocrine Carcinoma",
        "Islet Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "RAD001",
          "type": "DRUG"
        },
        {
          "name": "Octreotide Depot",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 67,
      "start_date": "2005-01",
      "completion_date": "2009-07",
      "has_results": true,
      "last_update_posted_date": "2026-07-06",
      "last_synced_at": "2026-11-18T20:13:16.792Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00113360"
    },
    {
      "nct_id": "NCT00004048",
      "title": "Radioimmunotherapy With or Without Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Thyroid Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "doxorubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "autologous bone marrow transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "indium In 111 monoclonal antibody MN-14",
          "type": "RADIATION"
        },
        {
          "name": "yttrium Y 90 monoclonal antibody MN-14",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Garden State Cancer Center at the Center for Molecular Medicine and Immunology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "16 Years to 80 Years"
      },
      "enrollment_count": 30,
      "start_date": "1998-09",
      "completion_date": "2002-05",
      "has_results": false,
      "last_update_posted_date": "2011-06-22",
      "last_synced_at": "2026-11-18T20:13:16.792Z",
      "location_count": 2,
      "location_summary": "Belleville, New Jersey • Paterson, New Jersey",
      "locations": [
        {
          "city": "Belleville",
          "state": "New Jersey"
        },
        {
          "city": "Paterson",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004048"
    },
    {
      "nct_id": "NCT04541108",
      "title": "Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "Rilvegostomig",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Volrustomig",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sabestomig",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AZD9592",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AZD9592 + Rilvegostomig",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "AZD9592 + Volrustomig",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "AZD9592 + Sabestomig",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "AZD9592 + Pembrolizumab",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Presage Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2021-07-26",
      "completion_date": "2031-12",
      "has_results": false,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-11-18T20:13:16.792Z",
      "location_count": 9,
      "location_summary": "Shreveport, Louisiana • The Bronx, New York • Chapel Hill, North Carolina + 5 more",
      "locations": [
        {
          "city": "Shreveport",
          "state": "Louisiana"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04541108"
    },
    {
      "nct_id": "NCT01916135",
      "title": "PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-Derivative",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Carcinoma",
        "Sarcoma",
        "Myeloma",
        "Lymphoma",
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "[18F]-SKI-249380",
          "type": "RADIATION"
        },
        {
          "name": "PET/CT scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Blood draws",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "21 Years to 90 Years"
      },
      "enrollment_count": 11,
      "start_date": "2013-07",
      "completion_date": "2020-04-23",
      "has_results": false,
      "last_update_posted_date": "2020-04-27",
      "last_synced_at": "2026-11-18T20:13:16.792Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01916135"
    }
  ]
}